In a major development for victims of the opioid epidemic, all 50 states, the District of Columbia, and U.S. territories have agreed to a $7.4 billion settlement with Purdue Pharma—the company widely known for manufacturing and aggressively marketing OxyContin.
The proposed settlement, filed in federal bankruptcy court in March 2025, is the result of years of legal battles and negotiation between Purdue Pharma, state attorneys general, and other stakeholders. If finalized, the settlement will be paid out over a 15-year period and would mark a significant shift in how accountability is handled in opioid litigation.
One of the most significant elements of the deal is that the Sackler family—who owned and controlled Purdue Pharma—will contribute up to $7 billion personally. This marks a key step in holding the family financially accountable for their role in the opioid crisis, according to officials like New York Attorney General Letitia James.
While the Sacklers maintain they did nothing wrong and deny any criminal conduct, the settlement structure represents a critical change: individuals who choose not to participate in the settlement may still retain the right to sue the Sackler family in civil court. In previous agreements, participants were often required to waive that right.
This deal follows a major legal roadblock in July 2024, when the U.S. Supreme Court struck down a prior bankruptcy plan due to objections raised by the Department of Justice’s bankruptcy watchdog. That earlier deal would have granted the Sacklers sweeping legal immunity. The new plan is expected to fare better in court, given its broader consensus and modified terms.
Attorneys representing communities harmed by the opioid epidemic say the settlement will funnel more than $7 billion into addiction treatment, prevention, and recovery services. That’s in addition to the over $50 billion already pledged by drug manufacturers, distributors, and retailers in previous nationwide opioid settlements.
The settlement still requires approval from a federal bankruptcy judge, but experts believe it is likely to move forward. If approved, this deal would be a landmark moment in the ongoing effort to seek justice for the millions of Americans affected by opioid addiction and overdose.
If you or a loved one was harmed by opioid misuse and suspect a pharmaceutical company may be at fault, you may still have legal options. Contact our class action team to learn whether you qualify to join an existing lawsuit or file an independent claim.
The information in this article is provided for general informational purposes only and does not constitute legal advice. Laws vary by jurisdiction and change frequently. Do not rely on this content as a substitute for advice from a licensed attorney familiar with your specific situation. Reading this article does not create an attorney-client relationship.
